ClariVest Asset Management LLC cut its holdings in Cooper Companies Inc (NYSE:COO) by 34.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 83,227 shares of the medical device company’s stock after selling 43,543 shares during the quarter. ClariVest Asset Management LLC owned about 0.17% of Cooper Companies worth $24,648,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in COO. Essex Savings Bank acquired a new stake in Cooper Companies in the 4th quarter valued at $25,000. Certified Advisory Corp acquired a new stake in Cooper Companies in the 4th quarter valued at $25,000. Executive Wealth Management LLC acquired a new stake in Cooper Companies in the 4th quarter valued at $34,000. Financial Gravity Companies Inc. acquired a new stake in Cooper Companies in the 4th quarter valued at $46,000. Finally, Quadrant Capital Group LLC increased its stake in Cooper Companies by 827.8% in the 1st quarter. Quadrant Capital Group LLC now owns 167 shares of the medical device company’s stock valued at $47,000 after buying an additional 149 shares during the last quarter. 95.95% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE:COO traded up $3.11 during midday trading on Monday, hitting $340.00. The stock had a trading volume of 342,247 shares, compared to its average volume of 342,654. The stock has a 50-day moving average price of $308.42. The company has a market capitalization of $16.67 billion, a P/E ratio of 29.57, a P/E/G ratio of 2.56 and a beta of 0.84. The company has a quick ratio of 0.68, a current ratio of 1.21 and a debt-to-equity ratio of 0.42. Cooper Companies Inc has a fifty-two week low of $228.65 and a fifty-two week high of $340.86.
In other Cooper Companies news, VP Randal Golden sold 1,154 shares of the business’s stock in a transaction that occurred on Wednesday, June 19th. The shares were sold at an average price of $328.16, for a total transaction of $378,696.64. Following the sale, the vice president now directly owns 1,148 shares of the company’s stock, valued at approximately $376,727.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jody S. Lindell sold 3,000 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $328.29, for a total transaction of $984,870.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 77,678 shares of company stock valued at $25,063,536. 1.70% of the stock is owned by corporate insiders.
Several equities research analysts have issued reports on COO shares. Wells Fargo & Co lifted their price target on shares of Cooper Companies from $305.00 to $325.00 and gave the company an “outperform” rating in a research note on Wednesday, March 6th. Stephens lifted their price objective on shares of Cooper Companies from $305.00 to $320.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. KeyCorp lifted their price objective on shares of Cooper Companies from $296.00 to $314.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $325.00 price objective on shares of Cooper Companies in a research note on Wednesday, March 6th. Finally, Raymond James lifted their price objective on shares of Cooper Companies from $300.00 to $325.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $315.36.
Cooper Companies Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Featured Article: Yield Curve
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.